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INTRODUCTION
Onychomycosis is a fungal infection of the nail bed, matrix (or) 
plate caused by dermatophytes, nondermatophyte moulds and yeasts. 1
It  accounts  for  50%  of  all  nail  diseases  and  30%  of  mycotic 
cutaneous infections. 2, 3
In developing countries, higher priorities to health issues for other 
diseases have resulted in low awareness of onychomycosis by physician 
and  general  public  alike.  Onychomycosis  is  all  too  often  regarded  as 
merely  a  cosmetic  problem  of  relatively  minor  importance,  to  seek 
treatment. This belief may have been supported by the adverse effects and 
long courses of treatment associated with some earlier antifungal agents. 
But now safer, effective, short course, systemic treatments are available.
Although onychomycosis is not life threatening, its high incidence 
and prevalence and associated morbidity  makes it  an important  public 
health problem, and it is the major cause of nail disease. 4
Hence  an  attempt  is  made  to  study  the  prevalence,  causative 
organism  and  therapeutic  response  to  topical  and  systemic  antifungal 
agents in onychomycosis.
REVIEW OF LITERATURE
HISTORY
In naming clinical infection due to dermatophytes, tinea precedes 
the Latin name for the involved body sites. eg. Tinea unguium refers to 
dermatophytic infection of nail.
The term onychomycosis is derived from the Greek word “Onyx” 
meaning  nail  and  “mykes”  meaning  fungus.  So  it  means  all  fungal 
infection of nail.
Dermatophyte infections have been described since ancient times. 
In  mid  1800s,  David  Gruby,  along  with  others  Remark  Schoenlein, 
Labert, Malmsten and Robin made major contributions to the field 5.
Sabouraud  established  the  current  classification  in  which 
dermatophytes  are  classified  by  genera.  In  the  1920s,  Hopkins  and 
Benham commenced the actual scientific study of medical mycology. 5
CLASSIFICATION OF FUNGI
Phylum Growth 
Form
Hyphae Sexual 
Propagules
Asexual 
Propagules
Zygomycota Moulds Broad few septa Zygospores Sporangiospores
Ascomycota Moulds 
Yeasts
Narrow regular 
septa
Ascospores Conidia
Basidiomycota Moulds 
Yeasts
Narrow regular 
septa clamp 
connections
Basidiospores Conidia
Deuteromycota Moulds 
Yeasts
Narrow regular 
septa
None Conidia
EPIDEMIOLOGY
Onychomycosis shows a worldwide prevalence rate of 2 – 18% 6. 
In  India,  incidence  varies  from  0.5  to  5%  in  general  population6. 
Prevalence rate among children varies from 0 to 2.6%. 7
Unlike in western countries where it is the frequent cause of nail 
disorders, in South Asia the prevalence of onychomycosis is relatively 
low. This was confirmed by large scale survey in Asia in late 1990s in 
which the prevalence of onychomycosis was lower in tropical countries 
(3.8%) than in subtropical countries and countries in the temperate zone 
18%.6
The  prevalence  rate  of  onychomycosis  is  determined  by  age, 
occupation, climate, living environment and frequency of travel. 8
Onychomycosis  is  more  frequent  among  men  than  women  and 
increases  with  age.  This  is  explained  by  their  being  relatively  more 
exposed to an environment conducive to the spread of organisms. 9
Personal and social factors
The reasons for increased incidence in adults are poor peripheral 
circulation, diabetes, repeated nail trauma, slow nail growth, suboptimal 
immune function, inactivity, inability to cut the toe nails and to maintain 
good foot care. 10
Lower incidence in children is due to reduced exposure to fungus, 
faster nail growth, smaller nail surface for invasion, lower prevalence of 
Tinea pedis. 10
Factors contributing to increased incidence of onychomycosis are,
 Diabetes, peripheral arterial disease, smoking.
 Sports  participation -  the  use  of  health  clubs,  commercial 
swimming pools, and occlusive foot wears for exercise. 11
 In small percentage of persons, it may be caused by genetic 
defect that causes an alteration in immune function. 12
 HIV,  Immosupressive  therapy,  cancer  therapy,  antibiotics, 
are other contributory factors.
Source of infection 13
Anthropophilic species - largely restricted to human skin.
Zoophilic species - having animal origins.
Geophilic species - originating in the soil.
Fungi causing onychomycosis
Up to 90% of mycotic toe nail infections and 50% of finger nail 
infections are caused by dermatophytes.
Dermatophytes 14 Geographical Distribution
Trichophyton rubrum World wide
T. mentagrophytes var interdigitale World wide
T. schoenleinii Eurasia, North Africa
T. tonsurans Europe, America
T.violaceum Africa, Eurasia
Epidermophyton floccosum World wide
Yeasts
It  causes  5% of onychomycosis  majority  of  which is  caused by 
Candida  albicans  &  occasionally  in  conjunction  with  mucocutaneous 
candidiasis. 15
Nondermatophyte Moulds
4%  cases  of  onychomycosis  are  caused  by  nondermatophyte 
moulds.16 They are Scytalidium dimidiatum, S.hyalinum17, Scopulariopsis 
brevicaulis,  Aspergillus,  Fusarium18,  Onychocola  canadensis19 
Syncephalastrum, Curvalaria, Aureobasidium paullulans20
PATHOGENESIS
Invasion of nails by fungus follows a common pattern starting with 
adhesion  between  arthoconidia  and  keratinocytes,  followed  by 
penetration  through  and  between  cells  by  a  variety  of  proteolytic 
enzymes.
Host resistance
- Unsaturated  transferrin  inhibits  the  growth  of 
dermatophytes  by  binding  to  iron  that  dermatophytes  need  for 
continuous growth. 21
- Presence of fatty acids from sebaceous glands 
which  inhibit  dermatophyte  growth  is  an  important  mode  of 
defence.
Immunology
- Dermatophytes can activate the alternative pathway of complement 
activation. 22
- Produce  catalase  and  superoxide  dismutase  which  may  act  as 
defenses against the phagocyte myeloperoxidase system.
- Development of cellular immunity via sensitised T lymphocytes is 
a key factor in immunological defence. 23
- Langerhan’s  cells  can  act  as  antigen  presenting  cells  for 
dermatophyte antigens. 24
CLINICAL PRESENTATION
It presents as whitish or yellowish streak ,a patch of discolouration 
at  free  edge near  lateral  nail  fold,  spreads  towards  base  and becomes 
brown, black. The nail plate becomes thickened, lifted up by subungual 
hyperkeratosis,  gross invasion may lead to massive destruction of  nail 
plate.25 Characteristically some nails are always spared. 
Tinea  unguium also   associates  with  dermatophytic  infection  in 
other areas of the body like Tinea pedis, Tinea manum etc... Candidal nail 
infection may be associated as paronychia & intertrigo.
CLINICAL TYPES25
Onychomycosis has been divided into five clinical types.
1) Distal and lateral subungual onychomycosis (DLSO).
2) Proximal subungual onychomycosis (PSO).
3) Superficial white onychomycosis (SWO).
4) Total dystrophic onychomycosis (TDO).
5) Endonyx onychomycosis.
DISTAL AND LATERAL SUBUNGUAL ONYCHOMYCOSIS 
This is the most common type, accounting for about 90% of cases 
of tinea unguium. The most common etiological agent is Trichophyton 
rubrum.
It starts by invasion of stratum corneum of the hyponychium of the 
distal nail bed (or) the lateral nail fold. Subsequently the infection moves 
proximally  in  the nail  bed and invades the ventral  surface  of  the nail 
plate, manifests as whitish to brownish yellow opanification.
Subungual hyperkeratosis results from a hyperproliferative reaction 
of  the  nail  bed in  response  to  the  infection  and leads  to  onycholysis. 
Splinter  hemorrhage  may  be  seen  probably  due  to  mild  inflammation 
compressing vessels. As the infective process continues, the invasion of 
the nail plate results in gross and total destruction of the nail. Increasing 
invasion of the ventral nail plate makes it thick, discoloured and friable. 
The  subungual  debris  also  provides  a  site  for  secondary  infection  by 
bacteria, other moulds and yeasts.
Nail invasion in distal lateral subungual onychomycosis
SUPERFICIAL WHITE ONYCHOMYCOSIS 
It is second most common type and accounts for 10% of all cases  26.   It 
produces distinct form of nail invasion in which the dorsal surface of the 
nail plate is eroded in well circumscribed powdery white patches often 
away from the free edge. The whole surface of the nail plate may be thus 
affected.
Although  more  common  with  Trichophyton  mentagraphytes  var 
interdigitale,  it  can  occasionally  be  seen  in  Trichophyton  rubrum 
infections and also occurs with certain nondermatophytes.
Toe  nails  are  usually  affected  but  in  AIDS  patients  superficial 
white onychomycosis of both finger and toe nails has been reported. In 
AIDS patients superficial infection may coexist with proximal nail plate 
invasion. Nail becomes rough and crumbly.
Nail invasion in superficial white onychomycosis
PROXIMAL SUBUNGUAL ONYCHOMYCOSIS
      This pattern is very uncommon particularly associated with AIDS 
patients. 26 It is most commonly caused by Trichophyton rubrum, 26 and 
also by T.mentagrophytes, T.tonsurans.
The first clinical sign is a whitish to brownish area on the proximal 
part of the nail plate. This area gradually enlarges to affect the entire nail. 
It is also associated with peripheral vascular compromise 
Nail invasion in proximal subungual onychomycosis
ENDONYX ONYCHOMYCOSIS
This  is  seen with  infection  caused  by dermatophytes  that  cause 
endothrix scalp infection notably Trichophyton soundanense27. The nail 
plate is scarred with pits and lamellar splits. The invasion occurs from the 
top surface but penetrates deeply into the nail plate.
Schematic drawing of nail invasion in endonyx onychomycosis
TOTAL DYSTROPHIC ONYCHOMYCOSIS                        
It  is  characterized  by  total  destruction  of  the  nail  plate  which 
usually may be the end result of other patterns of onychomycosis. The 
entire nail unit becomes thick and dystrophic.
ONYCHOMYCOSIS IN DIABETIC PATIENTS
Approximately  one  third  with  diabetes  are  affected  with 
onychomycosis. Diabetic patients suffering from decreased foot sensation 
are more prone to trauma, which damage the nail and nail matrix, opening 
portals  of  entry  for  the fungus to  infect  the nail.  The risk  factors  are 
peripheral  neuropathy,impaired  peripheral  circulation,  family  history, 
intake of immunosuppressive drugs, and duration of diabetes.28
Male diabetics have three times higher risk than female diabetics. 
Diabetes  with  onychomycosis  have  15%  rate  of  secondary  infection 
compared with 6% in diabetics without onychomycosis and three times 
greater risk of gangrene and foot ulcer.
ONYCHOMYCOSIS IN HIV
It  is  characterized  by  being  clinically  more  aggressive  with  a 
higher frequency of unusual presentations and resistance to conventional 
treatment.  Multiple fungal  species and unusual  opportunistic  fungi  are 
frequently cultured from HIV infected patients.
The  prevalence  of  onychomycosis  in  HIV  patients  has  been 
reported  to  be  15-40%.  It  can  be  an  early  manifestation  of 
immunosuppression  and  is  more  frequent  when  CD4 cell  count 
approaches 450 cells/µ. 29
ONYCHOMYCOSIS IN CHILDHOOD
Superficial  white  onychomycosis  is  more  common  and it  rarely 
involves  multiple  digits.  A  family  history  of  onychomycosis  may  be 
present and may be a factor in transmission as well as susceptibility.
Severe  onychomycosis  in  children  raises  concern  with  HIV  or 
other  forms  of  immunosuppression.  The  prevalence  of  childhood 
onychomycosis is 0 to 2.6% and tends to be associated with concomitant 
Tinea pedis or Tinea capitis. 7
COMPLICATIONS 30
- Nail disfigurement.
- Nail loss
- Secondary bacterial infections.
- Cellulitis
- Chronic utricaria
- Can spread to other areas of the body.
INVESTIGATIONS
Collection of Nail Specimen 31
Distal and lateral subungual onychomycosis
Samples  should  be  obtained  from the  nail  bed  and  ventral  nail 
plate.  It  is  very  important  to  try  to  collect  material  from  the  most 
proximal portion of the affected nail bed. This is the area most likely to 
contain viable fungi. The affected nail bed is exposed by removing the 
overlying onycolytic nail plate with the nail clipper, and then appropriate 
material is taken by scrapping the hyperkeratotic nail bed with the solid 
or disposable scalpel no.15 or small curettage.
Superficial white onychomycosis 
Shallow shaving with the disposable scalpel or gently scrapping the 
dorsum of nail with the curette will provide specimens for microscopy 
and culture.
Proximal subungual onychomycosis
The affected nail plate is exposed by perforating the proximal nail 
with the disposable punch or an electric drill. Samples are then obtained 
by scrapping the exposed nail plate with the disposable scalpel.
Endonyx onychomycosis
Viable fungi are present throughout the whole thickness of the nail 
plate.  Nail  clippings  can  therefore  be  sufficient  .  In  candidal 
onychomycosis infected material should be collected from the proximal 
edge.
DIRECT EXAMINATION
The material obtained is placed on a glass slide containing 40% 
KOH solution and is covered by a cover slip. The alkaline solution will 
digest the protein, lipids and most of the other epithelial debris that are 
present  but  the  fungal  filaments  resist  this  treatment  as  they  have 
chitinous wall.
The slide may be gently heated taking care to avoid boiling which 
leads to crystallization. Nail clippings take a long time to dissolve. When 
the material  has been softened by KOH, pressure on the cover slip  is 
applied to squash the specimen and then it is examined under the low 
power microscope.
Counter stains like chlorazol black and parker’s blue enhance the 
visibility of the fungus. Calcofluor fluorescent stain enhances the fungal 
cell  wall  by  staining  chitin32.  Microscopy  can  differentiate  between 
dermatophytes (hyaline hyphae) nondermatophytes (long sinus hyphae) 
and yeast (budding cells with pseudo hyphae) but species identification 
cannot be made from wet mounts.
CULTURE
Samples were inoculated into media – sabouraud’s dextrose agar 
with  chloramphenicol  and  cycloheximide,  SDA  with  chloramphenicol 
without  cycloheximide  both  were  inoculated  at  25o  C  and  37oC  and 
examined for dermatophytes,candida and moulds. If no growth observed 
after  6 weeks,  the sample was reported as negative.  In most  cases the 
culture was repeated more than once and in cases where contamination 
was suspected subculture was done. 33
Bacterial  growth is inhibited by the addition of chloramphenicol 
and gentamycin to the media. Yeast and nondermatophytic moulds tend 
to  grow more  rapidly  than  dermatophytes  in  a  matter  of  days  versus 
weeks respectively. 37
CULTURAL CHARACTERISTICS OF COMMONLY 
ISOLATED PATHOGENS
Dermatophytes 35
Trichophyton rubrum
a) Downy form
Colony 
Surface  of  the  colony  is  white,  downy  or  cottony.  The 
reverse  of  the  colony  is  initially  dark  brown  with  pale  cream 
border,  but  after  incubation  for  3-4  weeks  produces  the  typical 
deep red pigment characteristic of this species.
Microscopy
Small tear shaped, clavate or elongate microconidia are arranged 
along the sides of the hyphae.
b) Melanoid form
Colony
Brown melanoid pigment masks red pigment on reverse of 
the colony.
Microscopy
Small tear shaped microconidia are arranged along the sides 
of the hyphae.
c) Dysgonic form
Colony
Slow growing tiny deep red colonies with a brittle texture. 
This form is relatively unstable and will quickly revert to the more 
typical downy form.
d) Granular form
Colony
The surface is powdery or granular cream to pink and often 
raised and folded in the centre. The reverse is red brown.
Microscopy
Numerous smooth thin walled cylindrical or pencil shaped  
macroconidia are produced.
e) Yellow form
Colony
Smooth, leathery and yellow. Reverse is yellow.
Trichophyton mentagrophytes 36
Colony
Rapidly growing with white powdery and creamy centre. 
The reverse is reddish brown, often with a pale edge.
Microscopy
Spherical  microconidia  arranged  in  bunches,  spiral  
hyphae and macroconidia are present in some isolates. The fluffier 
downy isolates  have  pyriform microconidia  arranged  along the  
sides of the hyphae.
Trichophyton schoenleinii
Colony
Glaborous  or  velvety  usually  heaped  and  folded  with  a 
fringe of hyphae at the edge. The surface is white to cream and 
reverse pale.
Microscopy
Conidia  are  usually  absent.  Characteristic  dichotomously  
branching hyphae with flattened tips, termed chandelier or antler  
hyphae are present.
Trichophyton violaceum
Colony
Slow growing glaborous colonies have a waxy or leathery 
texture. They are deep red in color.
Microscopy
Microconidia  and  macroconidia  are  usually  absent.  
Chalmydoconidia and disorted hyphae may be present.
Trichophyton verrucosum 37
Colony
Very slow growing fungus, white or grey waxy colonies.
Microscopy
Short  hyphae  with  terminal  chalmydoconidia.  Clavate  or 
elongate  micro  conidia  may  be  present  along  the  sides  of  the 
hyphae. 
Rat tailed macroconidia may be produced on depleted media.
Non dermatophyte moulds
Scopulariopsis brevicaulis
Colony
On cycloheximide free medium, the fungus grows rapidly to 
produce a powdery cinnamon brown surface, often with radical or 
cerebriform folds. The reverse is cream to brown.
Microscopy
Chains of basipetal conidia are formed from annellides. The 
conidia are rough, lemon shaped with truncate base.
Fusarium
Requires cycloheximide free medium. In one week  pale pink or 
brownish flat colonies develop.
Microscopy
Numerous sickle shaped macroconidia and elliptical or oval 
micro conidia.
These  arise  from  short  phialidic  cells  in  colonies  of  fusarium 
oxysporum, long phialidic cells in colonies of fusarium solani.
Acremonium
Grow  in  media  both  with  and  without  cycloheximide.  In 
cycloheximide free medium white pink velvety colonies develop within 
one week.
Microscopy
Reveal elliptical conidia grouped at the tip of long phialides.
Scytalidium
In  cycloheximide  free  medium  fast  growing  colonies  with  an 
abundant aerial mycelium develop.
S.dimidatum
Initially white and become black and dark brown in a few days.
S.hyalinum
Remain white or creamy in colour.
Microscopy
Reveal the chains of arthrospores.
Aspergillus terreus
Colony
Rapidly growing powdery with a cinnamon brown surface 
and pale yellow reverse.
Microscopy
The  vesicle  at  the  apex  of  the  stout  conidiophore  bears 
metulae and phialides only on the upper two third of its surface. 
Long chains of smooth brown phialoconidia are produced which 
form a columnar head.
Aspergillus niger
Colony
Coarse black granules against the creamy colony surface.
Microscopy
Globose vesicles with biseriate phialides large echinulate jet 
black conidia in chains. Foot cells are present.
Rhizopus
Colony
Cottony to wooly gray colonies that rapidly fill the Petri dish 
or test tube. Salt and pepper colony surface.
Microscopy
Broad irregular hyphae that are aseptate or sparsely septate. 
Well developed rhizoids. Branching sporangiophores with hemispherical 
columellae arising form nodes adjacent to rhizoids.
Curvalaria
Colony
Species are velvety or woolly with dark brown to black to 
olive green pigment.
Microscopy
Dark hyphae and slender geniculate conidiophores.
Syncephalastrum
Colony
Yellow to  yellow green  velvety  to  powdery  colonies  and 
form concentric rings of growth where conidiation is heavy.
Microscopy
Unicellular  hyaline  phialoconidia  on  short,  plump  flask 
shaped phialophores. Clusters of subglobose to ellipitical conidia in balls 
at the tip of the phialides.
Aureobasidium pullulans
Colony
White  to  yellow  colonies  with  a  wrinkled  or  folded 
topography.  As  arthroconidia   are  produced,  colonies  become  shiny, 
mucoid, dark brown to black.
Microscopy
Delicate thin walled hyphae and ellipitical conidia.
Candida albicans
Colony
White to cream and soft in texture.
Microscopy
Reveals budding yeast cells. The production of  filaments is 
best  examined on depleted media such as cornmeal  agar or rice 
extract agar supplemented with Tween 80.
It differs from most other species of candida by production 
of  rudimentary  true  hyphae  (germ  tubes)  when  inoculated  into 
serum and incubated at 37oC for 2 – 4 hrs.
HISTOPATHOLOGY
Histological examination of the nail is useful alternative to culture / 
KOH. 41
Nail clippings may be sent to laboratory for diagnosis in formalin 
filled container (or) an incisional biopsy may be performed to confirm the 
diagnosis.
Staining in the laboratory should be performed with periodic acid 
shiff,  methanamine  silver,  Haematoxyllin  eosin,  toludine  blue  stain  to 
reveal fungal elements  34.Presence of glycogen and mucoproteins in the 
cell walls of fungal hyphae appears red indicating a positive stain. 28
Haemotoxylin eosin shows basophilic, refractile structures. If fungi 
are present in the horny layer they usually are sandwiched between two 
zones  of  cornified  cells,  the upper  being orthokeratotic  and the  lower 
consisting partially of para keratotic cells called “Sandwich sign”.
Histopathologic  examination  shows  psoriasiform  hyperplasia, 
parakeratosis,  thinned  ridges,  narrow suprapapillary  plates  and  dilated 
tortuous capillaries. It dosen’t identify the species of causative pathogen.
Unna was the first to give a detailed histopathological description 
of infected nails.
Advantages
- The result is much faster than culture usually 3 days versus 
3 weeks.
- Histopathology is more often positive than culture.
- Only means to differentiate onychomycosis from nail psoriasis, 
lichen  planus,  alopecia  areata,  nail  eczema  and  other 
inflammatory nail disorders.
Immuno histochemistry 34
With this procedure, nail sample sections are exposed to labeled 
antibodies  specific  to  suspected  fungal  pathogens.  Monoclonal  anti 
Trichophyton  spp  (dermatophytes),  anticandida  spp  (yeasts),  anti 
aspergillus spp (moulds) antibodies are used for the identification of the 
fungi.  Visualization  is  achieved  by  direct  immunofluorescence, 
immunoperoxidase or avidin biotin complex methods.
Flow cytometry
Flow  cytometry  is  based  on  the  ability  to  identify  molecular 
variances among fungal species. Dissociated nail samples are filtered to 
collect single fungal cells that are analyzed with a flow cell sorter on the 
basis of DNA and protein detection, cell size and cell granulosity.
In vivo confocal microscopy
It  is  a  highly  discriminatory  technique  that  facilitates  the 
examination of living tissue. Reflected light is used to penetrate the nail 
at various depths, thus imaging layers of the nail optically. Detection of 
fungal hyphae in the nail plate and nail bed depends on light penetration 
into the tissue and the reflectivity of the structures being observed.
Scanning electron microscopy
It  generates  three  dimensional  images  of  high  resolution,  high 
magnification and large focal depth. Cross sectioned nail specimens are 
fixed,  dehydrated  and  dried  for  viewing  with  a  scanning  electron 
microscope,  allowing  for  detailed  imaging  of  the  spatial  orientation, 
penetration and integration of fungal hyphal elements in the nail plate.
Polymerase chain reaction methods
PCR provides sensitive and specific detection of DNA sequences. 
DNA  extracted  from  nail  specimens  is  amplified  by  PCR  methods, 
detection & differentiation of dermatophytes,  nondermatophyte moulds 
and yeasts is achieved by amplification with specific fungal DNA primer 
sets.Subsequent digestion by restriction enzymes in restriction fragment 
length polymorphism analysis  allows  identification  of  fungal  species, 
strain and sub type.
DIAGNOSIS OF ONYCHOMYCOSIS
Based on criteria formed by Scher et al (J Am Acad Dermatol June 2007)
Clinical
Primary Criteria
 White / yellow or orange/brown patches or streaks.
Secondary criteria
 Onycholysis
 Subungual hyperkeratosis / debris
 Nail plate thickening
Laboratory
 Positive microscopic evidence
 Positive culture of fungus
Nondermatophyte moulds have been cultured from onychomycotic 
nails,  but  at  times  may  be  contaminants.  Certain  criteria  need  to  be 
fulfilled before these are considered as primary pathogens. 38
The criterias are, 39
 If a dermatophyte is isolated on culture from nail clippings, it is 
considered a pathogen.
 In case of culture of a mould or yeast, it should be considered a 
pathogen only if hyphae, spores or yeast cells are seen on microscopic 
examinations.
 Confirmation  of  an  infection  by  a  nondermatophyte   mould 
requires  isolation  of  the  organism on  at  least  5  out  of  20  inocula 
without concurrent isolation of a dermatophyte.
 Isolation of same mould from three consecutive nail samples.
As a rule, nondermatophytic onychomycosis favours diseased or 
aged nails, toe nails are the usual sites of involvement. 
Most  isolates  can  be  identified  from the  primary  culture,  but  if 
sporulation is poor, a number of media may be used to encourage the 
production of conidia, including potato dextrose agar and lactrimel agar.40
DIFFERENTIAL DIAGNOSIS 43
a) Hand Eczemas
May  develop  dystrophic  nails  with  transverse  ridges. 
Presence  of  or  history  of  eczematous  lesions  would  help  in 
differentiation.
b) Psoriasis
Presence of symmetrical nail involvement and skin lesions 
in  psoriasis  help  in  differentiation.  Pits  are  characteristic  and 
distinguishing features. Pits are uncommon in fungal infections.
c) Lichen Planus
Thinning  is  the  commonest  change  and  there  are  usually 
associated  cutaneous  lesions,  other  findings  include  longitudinal 
ridging,  pterygium  unguis,  nail  loss,  twenty  nail  dystrophy, 
hyperkeratosis, onycholysis.
(d) Leukonychia (Acquired / congenital)
Superficial white  onychomycosis needs to be distinguished. 
(e) Paronychia
May be caused by bacterial infection.
(f) Darier’s disease
Nails show ‘V’ shaped wedges.
(h)Pachyonychia congenita
(i) Reiter’s syndrome
(j) Norwegian scabies
(k)Pseudomonas infection
(l) Neoplastic
Subungual melanoma, Subungual fibroma
(m) Yellow nail syndrome
(n)  Usage, Degenerative, Age related disorder 
(o) Onycholysis
(p)    Atherosclerosis, venous disorder, peripheral vascular disease.
(q)  Repeated trauma.
(r)   Allergic contact dermatitis, collagen vascular diseases.
MANAGEMENT OF ONYCHOMYCOSIS
There  are  several  factors  that  need  to  be  considered  in  the 
management of onychomycosis.
a) Drugs (efficacy, adverse effects profile, dosage schedule, duration 
of  therapy,  relapse  rates,  monitoring  schedule  and  cost 
effectiveness).
b) Patient  and  disease  profile  (the  location  and  extent  of 
onychomycosis, etiologic agents, any concomitant health problems, 
and concurrent medications.
TOPICAL ANTIFUNGAL AGENTS
The have  sometimes  been considered for  the  treatment  of  early 
onychomycosis,  in  the  absence  of  nail  matrix  involvement.  The more 
commonly used topical agents for the treatment of onychomycosis are 5% 
amorolfine  nail  lacquer,  8%  ciclopiroxolamine  nail  lacquer,  28% 
ticonazole and bifonazole with 40% urea paste. 44
AMOROLFINE
Amorolfine  is  a  morpholine  derivative.  It  is  active  against 
dermatophytes  and  dimorphic  fungi  with  activity  against  yeasts  and 
moulds being more variable. 45
Mechanism of action
Amorolfine  interferes  with  the  steps  in  the  sterol  biosynthesis 
pathway. These include the enzymes Delta 14 reductase and Delta 7 – 8 
isomerase.  An alteration in the sterol  content  of the fungal  membrane 
may result  in hyper fluidity and permeability changes with the fungus 
eventually becoming nonviable.47
When  amorolfine  is  applied  to  the  nail  surface  the  solvent 
evaporates to leave a highly concentrated deposit of drug in an occlusive 
film on the nail. This acts as deposit from which amorolfine penetrates 
and diffuses through the nail plate to nail bed over the next seven days. 26
Duration
Once or twice weekly 6 months for finger nails, 12 months for toe 
nails.
Indications
For  mild  cases  of  distal  and  lateral  subungual  onychomycosis, 
> 18 years of age.
Contraindication
Hypersensitivity, pregnancy, breast feeding, under 18 years of age.
Adverse effects
Slight redness, transient burning sensation in the areas of the nails 
after application of the lacquer. 47
Interaction
Not to use nail polish and artificial nails during treatment. It is not 
systemically absorbed and no known interaction with other drugs. 26
CICLOPIROXOLAMINE
It is a hydroxypyridone topical anti fungal and fungicidal against 
Trichophyton  rubrum,  T.mentagrophytes,  Epidermophyton  floccosum, 
Micosporum canis and Candida albicans.
Mechanism of action
It inhibits transport of certain essential substrates into fungal cells 
and interferes with the synthesis of DNA, RNA and proteins in growing 
cells. The main mode of action is its high affinity for Fe3+, Al3+ 48. The 
inhibition  of  these  essential  cofactors  affects  mitochondrial  electron 
transport processes thereby impairing microbial metabolism. 49
It also reduces the activity of catalase and peroxidase which are 
responsible for the intracellular degradation of toxic peroxides.
Adverse effects
Periungual  erythema,  burning  or  tingling  sensation  at  the 
application site. 50
TICONAZOLE (28%) SOLUTION
It  is  an  imidazole  with  the  broad  spectrum of  antifungal 
activity.  The organisms that  responded includes  Trichophyton rubrum, 
Scytalidium dimidiatum and acremonium species.
Other  topical  therapies  are  1%  bifonazole  and  40%  urea, 
clotrimazole  cream  and  solution,  miconazole  tincture,  glutaraldehyde 
10% solution, 1% fluorouracil in propylene glycol ,a tincture containing 
triacetin,  sodium  propionate,  benzalkonium  chloride,  cetylpyridinium 
chloride and chlorozylenol,  vitamin E, naftifine hydrochloride 1% gel, 
topical ketoconazole under occlusion following nail avulsion.
SYSTEMIC ANTIFUNGAL AGENTS
GRISEOFULVIN
It  is  an  oral  antifungal  agent  derived  from  penicillium 
griseofulvum and has narrow spectrum of action against dermatophytes. 51
Mechanism of action
It inhibits the formation of intracellular microtubules, disrupts the 
mitotic spindle and prevents cell division of the fungus. 52
Pharmacokinetics
Griseofulvin is poorly absorbed after oral administration because 
of  its  poor  solubility  in  water.  The  bioavailability  of  this  agent  is 
improved by taking with a fatty meal and also intake in micronized form. 
51
The peak serum concentration occurs approximately 4 hours after 
drug administration. 84% is bound to plasma protein, albumin and has 
low  affinity  for  keratin.  Prolonged  administration  of  griseofulvin  is 
required because the drug is fungistatic and persists in the nail for a very 
short time approximately 2 weeks after discontinuation of treatment. 52
Griseofulvin is predominantly metabolized in liver and excreted 
in urine. Its half life is 9 to 22hrs.
Indications
Griseofulvin has a narrow spectrum with effectiveness extending 
to dermatophytes only. 54
Interactions
Contraindicated  in  individuals  with  porphyria,  hepatocellular 
failure and hypersensitivity.
Warfarin  needs  dosage  adjustment.  Dose  of  grisefulvin  is  to  be 
increased  while  on  barbiturates.  It  should  not  be  administered  during 
pregnancy because of the risk for developing conjoint twins. 55
Adverse effects
Hypersensitivity, oral thrush, nausea vomiting, epigastric distress, 
diarrhoea, headache, dizziness, insomnia, mental confusion. 55
Dose: 500mg / day 6 months for fingernail onychomycosis, 12 months 
for toe nail onychomycosis.
FLUCONAZOLE
It  inhibits  fungal  lanosterol  14  alpha  demethylase.  The  oral 
bioavailability is greater than 90%, not seem to be affected by gastric PH. 
The  peak  plasma  concentration  is  between 1  and  2  hours,  half-life  is 
between 20 and 50 hours.
Fluconazole has low lipophilicity and low level of plasma protein 
binding, primarily cleared by the renal system.
Indications
Fluconazole  has  proved   safe  and  effective  in  the  treatment  of 
fingernail and toe nail onychomycosis. 56
Dose
150 mg, 300 mg (or) 450 mg once weekly for 9 – 12 months.
Interaction
Contraindicated with cisapride, terfenadine. Cemiditine, rifampicin 
decreases  plasma  concentration  of  fluconazole.  Hydrochlorothiazide 
increases  plasma  concentration  of  fluconazole.  It  increases  plasma 
concentration of cyclosporin, astemizole, glipizide, glyburide, phenytoin, 
rifabutin, tacrolimus, theophylline, zidovudine.
Prothrombin time is increased with anticoagulant.
Adverse effects
Headache,  skin  rash,  nausea,  vomiting,  diarrhoea,  palpitations, 
sweating, fever.
ITRACONAZOLE
It is a triazole derivative & disrupts the synthesis of ergosterol.
It is highly lipophilic, oral bioavailability is maximal when taken 
with a full meal. 57 Approximately 95% is bound to plasma albumin. It 
has a high affinity for keratinized tissues and has been detected in distal 
finger nail material after 1 week of therapy. It persists for upto 6 months 
after discontinuation of therapy more or less unchanged. 58
Itraconazole  is  predominantly  metabolised  by  the  CYP 3A4  iso-
enzyme,  the major  metabolite  is  hydroxyitraconazole.  18% is  excreted 
through feces.  Approximately 40% of the dose is  excreted as inactive 
metabolites in the urine.
Indications
Effective for dermatophytes, candida, nondermatophyte molds may 
also respond well to itraconazole.
Drug Interactions
Quinidine, pimozide, midazolam, triazolam, cisapride, astemizole, 
terfenadine, lovastatin, simvastatin are contraindicated . 
Plasma  concentration  is  decreased  by  carbamazepine, 
phenobarbitone,  pheytoin,  rifabutin,  rifampin,  antacids,  H2  blockers, 
proton pump inhibitors, nevirapine.
Plasma concentration is increased by erythromycin, clarithromycin, 
indinavir, ritonavir. Oral contraceptives may be ineffective.
Adverse effects
Headache, rhinitis, sinusitis, diarrhoea, flatulence, abdominal pain, 
dizziness,  rash,  cystitis,  urinary  tract  infection,  gastritis,  fever,  pain, 
tremor, herpes zoster, abnormal dreaming. Rare cases of congestive heart 
failure and pulmonary edema have been reported. 57
TERBINAFINE
It is an allylamine class of antifungal agent discovered in 1970s.
Terbinafine  is  primarily  fungicidal  against  dermatophytes, 
aspergillus species, scopulariopsis brevicaulis, blastomyces, histoplasma 
capsulatum. The activity against yeast is more variable.
The primary target of terbinafine in fungi is the membrane bound 
enzyme, squalene epoxidase. This produces ergosterol deficiency, which 
interferes with membrane function. On the other hand, accumulation of 
squalene  results  in  the  deposition  in  lipid  vesicles  with  disruption  of 
cellular membranes. 59
Terbinafine is well absorbed (>70%) and the bioavailability is 40% 
as a result of first pass metabolism. Greater than 99% of terbinafine is 
nonspecifically bound to plasma proteins. Peak plasma concentration is 
within 2hrs after a single dose. The allylamine is extensively distributed 
and extremely lipophilic.
Terbinafine  is  extensively  metabolized,  its  main  metabolite  is 
demethyl terbinafine.  Approximately 70% of the administrated dose is 
eliminated in the urine.
When terbinafine  250mg /  day  was  administered,  the  drug was 
detected in peripheral nail clippings after 7 days of medications. Mean 
half life is 22 days. 60
Half of the drug concentration is still retained for 90 days at levels 
higher than the MIC values of most nail pathogens by a factor of 15 – 50 
times
Dosage
250mg/day  for  6  weeks  and  12 weeks  in  fingernail  and toenail 
onychomycosis respectively.
Interactions
Its plasma concentration is decreased by rifampicin and Increased by 
cimetidine,  terfenadine.  It  increases  the  concentration  of  caffeine, 
theophylline and decreases the concentration of cyclosporin.
Adverse effects
Nauses,  diarrhoea,  abdominal  pain,  dyspepsia,  rash,  uticaria, 
eczema.
Rare cases of symptomatic hepatic injury have been reported. Terbinafine 
may also cause headache, taste disturbances and white cell disturbances. 
Adverse effects associated with terbinafine are usually mild, transient and 
reversible on discontinuation of therapy. 61
TREATMENT OF ONYCHOMYCOSIS IN CHILDREN7
Topical  antifungals  can  better  penetrate  the  thin  nail  plate  of 
children and are used as first choice treatment.
Terbinafine,  Itraconacole  and  Fluconazole  have  all  been  used 
safely in children.
ADJUVANT THERAPY
Surgical or chemical nail avulsion with 40% urea may be useful in 
patients with severe onycholysis, extensive nail thickening or longitudinal 
streaks in the nail.
Topical antifungal agents are of limited efficacy when used alone 
but may result in a more rapid cure when used in conjunction with the 
newer systemic compounds.
STRATEGIES TO IMPROVE EFFICACY OF TREATMENT 62
a) Accurately identify pathogenic organism to ensure proper selection 
of antifungal agent.
b) To distinguish from psoriasis or other diseases.
c) Recognize nail characteristics
− Thick nails
− Lateral infection
− Dermatophytoma
− Severe Onycholysis
d) Recognize patient characteristics
− Poor perfusion
− Diabetic
− Elderly
− Immunocompromised
e) Recognize and implement techniques to increase success:
− Debride thick nails, onycolytic nails, dermatophytomas.
− Choose medications that  are safe  and convenient  for  the 
patient and appropriate for the infecting organism.
− Assess  the  possibility  or  need  for  prophylactic  therapy 
(topical for long term follow up of cured nails, treatment 
for tinea pedis).
− Combination therapies (If standard therapy fails).
f) Educate patient about onychomycosis:
− Need for compliance with therapy and follow up.
− Educate about toe nail hygiene to prevent recurrence.
Poor prognostic factors 42
− Area of nail involvement > 50%
− Significant lateral disease.
− Subungual hyperkeratosis >2mm
− White/yellow or orange/ brown streaks in the nail.
− Total dystrophic type.
− Non responsive organisms.
− Patients with immunosuppression.
− Diminished peripheral circulation.
Recurrence
It is not uncommon. Recurrence often implies that although the 
clinical signs have resolved,  either mycological  cure was not achieved 
with  the  initial  treatment  or  a  new infection  has  developed during or 
immediately after treatment period.
Mycological cure
Define as negative KOH microscopy and culture results.
Clinical cure
Expressed as % of nail plate that is visibly clear of infection.
Complete cure
Includes mycological and clinical cure.
AIMS AND OBJECTIVES
To Study
 Age and sex distribution of the patients with  onychomycosis
 Clinical types of onychomycosis
 Isolation of causative organisms
 Precipitating factors
 Associated dermatological conditions
 Associated systemic diseases.
 Therapeutic  trial  with  systemic  terbinafine  alone,  topical 
amorolfine alone and both together.
MATERIALS AND METHODS
This randomized single-blind longitudinal clinical comparative 
study was undertaken during the period of Aug 2008 to July 2009. 108 
patients  presenting  to  our  department  out  patient  clinic  with  clinical 
features  of  finger  nail  or  toe  nail  onychomycosis  (eg.  Discolouration, 
thickening, crumbling or destruction of nail plate, subungual debris and 
onycholysis) were subjected to detailed history, clinical examination and 
investigations like potassium hydroxide (KOH) mount and culture from 
nail clippings/ scrappings.
89 patients were either KOH, culture or both positive. Among 
these who had received systemic/ topical antifungal therapy in the last six 
months,  pregnant,  lactating,  those  with  elevated  hepatic  enzymes,  not 
willing for study were excluded from the drug trial. Only 60 patients were 
randomly  selected  for  study and divided into  three  groups (A,  B,  C). 
Group A received oral terbinafine alone 250mg daily for 6/12 wks, Group 
B received topical amorolfine alone once weekly for 6 months, Group C 
received oral terbinafine daily for 6/12wks   plus topical amorolfine once 
weekly for 6 months. 
The  patients  were  evaluated  at  6weeks,  12  weeks  and  24 
weeks.  During  these  visits  they  were  assessed  for  the  growth  of  the 
normal and healthy nail plate and were inquired for any adverse effects of 
the  drugs.  In  addition,  microscopic  examination  and  culture  of  nail 
material were done at 12, 24 weeks.
Direct microscopy was done after overnight incubation of the 
nail  specimen  in  40%  KOH  for  the  presence  of  fungal  mycelia  and 
spores. All the nail specimens were cultured on sabouraud dextrose agar 
(SDA) with chloramphenicol  and with  or  without  cycloheximide.  The 
cultures were observed twice a week for a period of 4 weeks and were 
discarded if there was no growth at the end of 4 weeks. The culture tube 
was  examined  for  colour  of  the  colony  (on  the  surface  and  reverse), 
texture, and rate of growth.
In the presence of growth, a loopful of growth was taken and 
examined using a lactophenol cotton blue mount. Slide culture was also 
done if required and was examined for characteristic morphology.
The criteria used for the diagnosis of dermatophytes were,
- If a dermatophyte was identified on KOH mount and/or 
isolated on culture, it was pathogenic.
The  criteria  used  for  the  diagnosis  of  Nondermatophytic 
moulds [NDM] were, 
- demonstration of fungal filaments on KOH mount and 
- Isolation of NDM in culture.
Isolation  of  NDM  on  three  occasions  was  considered  as 
pathogenic. 
Proposed  definitions  of  cure  when  assessing  patients  with 
onychomycosis in clinical trials (Based on criteria formed by Scher et 
al (J Am Acad Dermatol June 2007)
Criteria for cure
A) 100%  absence  of  clinical  signs  of  onychomycosis  (mycology  not 
required)                 OR
B) Negative mycological laboratory results with one or more of following 
clinical signs
i) Distal  subungual  hyperkeratosis  or  onycholysis  leaving  less  than 
10% of nail plate affected
ii) Nail plate thickening that does not improve with treatment because 
of comorbid condition
Criteria for noncure
A) Presence of positive mycological results.
B) Any one  of  the  4  clinical  signs,  even  in  the  presence  of  negative 
mycological results 
i) Residual  major  changes (>10%) of the nail  plate compatible  with 
dermatophyte infection
ii) White / yellow or orange brown / patches or streaks in or beneath the 
nail.
iii)Lateral onycholysis with debris in an otherwise clear nail plate.
iv) Hyperkeratosis on the lateral nail plate / nailfold edge.  
The results were recorded and a detailed analysis was done.
OBSERVATIONS AND RESULTS
Out of 89 patients, 37 were male patients (41.5%) & 52 were 
female patients (58.5%) giving a sex ratio of 1:1.4. 
Table 1
AGE & SEX WISE DISTRIBUTION
Age in years No. of Male No. of Female
0-10 - 1
11-20 yrs 5 4
21-30 yrs 8 7
31-40yrs 7 12
41-50yrs 9 8
51-60yrs 4 17
>60 4 3
Total 37 52
The most commonly infected was the 51-60 yrs age group[21 
patients]  followed  by  31-40 yrs  age  group[19  patients]  41-50  yrs  (17 
patients), 21-30 yrs (15 patients), <20yrs (10 patients) and above 60 yrs 
(7 patients). Infection was less common in the age group below 10 years, 
whereas infection was high above 50 years. Youngest age in this study 
was 3 years. Oldest age was 70.
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With regard to occupational exposure, 37 patients (41.5%) 
were housewives, 12 patients (13.5%) were hotel staffs.Manual labourers 
(8.9%), and farmers (5.6%) were next commonly affected.
The duration of illness was < 6 months in 41 patients (46%), 
6 months to 1 year in 21 Patients (23.6%),1-2 years in 7 patients(7.9%), 
>2 years in 20 patients (22.5%).
12 patients gave history of trauma prior to nail infection and 
family history of onychomycosis  was reported by 4 patients.  Smoking 
history was found in 12 patients, alcohol intake in 9 patients.
36 patients  showed only fingernail  involvement,  11 patients 
only toe nail involvement,  42 patients had both fingernail and toe nail 
involvement at the time of presentation.
NAIL INVOLVEMENT
11
42 36
FINGER NAILS
TOE NAILS
BOTH NAILS
TABLE - 2
CLINICAL TYPES
Type No of Patients Percentage
DLSO 40 44.9%
TDO 26 29.2%
PSO 7 7.8%
SWO 1 1.1%
DLSO & TDO 10 11.2%
PSO / TDO 4 4.5%
SWO / TDO 1 1.1%
Distal and lateral subungual onychomycosis (DLSO) was the 
most  frequent  clinical  pattern  noted  in  40  patients  followed  by  Total 
dystrophic  onychomycosis  (TDO)  in  26  patients,  DLSO&TDO  in  10 
patients, proximal subungual type in 7 patients. Least common type was 
superficial white onychomycosis noted in 1 patient.
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Dermatological conditions associated with onychomycosis
S.No Dermatological condition No. of Patients
1 Vitiligo 3
2 Psoriasis 3
3 Hansen’s disease 2
4 Intertrigo 2
5 Keratolysis punctata 2
6 Perforating folliculitis 1
7 Morphea 1
8 Nevus achromicus 1
9 Tinea versicolar 2
Systemic diseases associated with onychomycosis
S.No Associated systemic disorders No. of Patients
1 Diabetes mellitus 11
2 Hypertension 10
3 Renal transplant 2
4 Hypothyroidism 1
5 Seizure disorder 1
6 Filaria 1
LAB DIAGNOSIS
14
23
52
KOH POSITIVE
CULTURE POSITIVE
BOTH POSITIVE
Of the 89 specimens studied fungal elements were identified by positive 
KOH mounts with culture negative in 23 specimens   and 14 specimens 
showed KOH negative and culture positivity. Both culture & KOH 
positivity was seen in 52 specimens.
FUNGAL PATHOGENS IDENTIFICATION BY CULTURE
29
12
15
DERMATOPHYTES
YEASTS
MOULDS
Yeasts & dermatophytes were isolated in 15, 12 specimens respectively, 
while  nondermatophytic  moulds  were  isolated  in  29  samples. 
ISOLATED FUNGAL PATHOGENS
1. Yeasts
Organism No of patients Percentage
Candida 7 46.6%
Nonalbicans candida 8 53.4%
2. Moulds
organisms No of patients percentage
Aspergillus niger 15 51.7%
Rhizopus 5 17.2%
Syncephalastrum 4 13.8%
Curvalaria 2 6.9%
Aureobasidium pullulans 2 6.9%
Scopulariopsis 1 3.4%
3. Dermatophytes
Organisms No of patients Percentage
Trichophyton rubrum 5 41.6%
T.verrucosum 2 16.6%
T.schoenlenii 2 16.6%
T.mentogrophytes 2 16.6%
T.violaceum 1 8.3%
During  the  course  of  the  study,  two  patients  in  Group  A,  four 
patients in Group B, one patient in Group C were lost in follow up period 
& were excluded from the analysis of results.
At sixth month follow up, 
Mycological response in the study group
Fungal Isolate Group A
N=18
Group B
N=16
Group c
N=19
Cured Total Cured Total Cured Total
Dermatophytes 4 4 3 5 3 3
Yeasts 3 4 2 4 4 5
Nondermatophytes
(moulds)
5 9 4 7 6 8
KOH positive 1 1 - - 3 3
Overall response 13 18 9 16 16 19
Overall percentage 72% 56% 84%
Mycological  cure  rate  was  72%,  56%,  84%  in  Group  A,  B,  C 
respectively.
Clinical response in the study group
Group Cured Total Percentage
A 11 18 61%
B 8 16 50%
C 14 19 74%
Clinical cure was observed in 61%, 50%, 74% patients in group A, B, C 
respectively.
No major adverse effect due to drug was observed in this study.
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Distal and lateral subungual onychomycosis.
Superficial white onychomycosis.
Proximal subungual onychomycosis.
Total dystrophic subungual onychomycosis.
Tinea unguium with Tinea manum
3 yrs old child with dystrophic thumb & 
middle finger and paronychia.
GROUP –A
Dystrophic thumb nail before treatment.
Normalization of proximal edge of nail after 6 weeks of treatment with 
oral terbinafine
DHAVAMANI
DHAVAMANI
GROUP –B
Blackish discolouration and thickened finger nails.
Change in discolouration & decrease in subungual hyperkeratosis 
noted after 6 months of topical amorlfine application.
GANESAN
GANESAN
GROUP –C
Onycholysed finger nails before treatment  
Normalization of nail plate after treatment with oral terbinafine and 
topical amorolfine for 6 weeks
RAMBHAI
RAMBHAI
REFRACTILE, SEPTATE FUNGAL HYPHAE SEEN IN 
POTASSIUM HYDROXIDE MOUNT.
              HYPHAE SEEN WITHIN STRATUM CORNEUM IN 
PERIODIC ACID SCHIFF STAIN
Candida albicans                    Syncephalastrum
         WHITE TO CREAM YELLOW GREEN VELVETY 
      COLOURED COLONY     POWDERY COLONY
CULTURE
(MACROSCOPY)
WHITE COTTONY COLONY DEEP RED PIGMENT
Trichophyton violaceum
 WAXY LEATHERY COLONY DEEP RED COLOUR ON REVERSE
Trichophyton verrucosum  Trichophyton schoenleinii
  
WHITE WAXY COLONY                WHITE VELVETY HEAPED AND 
          FOLDED COLONY 
(Trichophyton rubrum)
SMALL TEAR SHAPED, CLAVATE MICROCONIDIA ALONG THE SIDES OF 
THE HYPHAE ON LACTOPHENOL COTTON BLUE MOUNT 
(Trichophyton verrucosum)
SHORT HYPHAE WITH TERMINAL CHALMYDOCONIDIA ON
LACTOPHENOL COTTON BLUE MOUNT
(Trichophyton mentagrophytes)
SPHERICAL MICROCONIDIA, SPIRAL HYPHAE SEEN ON 
LACTOPHENOL COTTON BLUE MOUNT
Trichophyton schoenlenii
CHANDELIAR (OR) ANTLER HYPHAE SEEN
DISCUSSION
Onychomycosis can occur at any age but is most commonly 
seen during 40 – 60 years of age and is unusual before puberty. 63
In our study the common age group affected was between 31-
60 years.
Incidence of onychomycosis was more in females than males 
attributed due to higher number of female respondents in our study. The 
sex ratio is [1:1.4].
Among  the  females  the  majority  were  housewives  37/52 
(71%).  This  is  due  to  frequent  contact  with  water  and  detergent  that 
damages the cuticle, which then favours the invasion by fungi.
Trauma  was  the  major  predisposing  factor  in  our  study, 
followed by diabetes mellitus. A study by Dogra S, Kumar B, Bhansali A 
et al., concluded that diabetics were 2.5 times more likely than controls to 
have  onychomycosis  because  of  impaired  circulation  and  peripheral 
neuropathy.
The number of patients with each individual disease was too 
low to  draw any  conclusions  on  the  prevalence  of  onychomycosis  in 
conjunction with these individual diseases.  (Vitiligo,Psoriasis,Hansen’s, 
Hypothyroidism, Intertrigo, Keratolysis punctata, Perforating folliculitis, 
Renal transplant, Filaria, Morphea, Seizure disorder).
In our study finger nails were involved more often than the toe 
nails.  This has also been reported by other authors (64,  65). A higher 
incidence of fingernail onychomycosis may be a result of the increased 
chance  for  trauma.  Moreover,  finger  nail  infection  is  more  likely  to 
arouse the patient’s concern.
Distal  and  lateral  subungual  onychomycosis  was  the  most 
common clinical  pattern observed in  our  study which is  in  agreement 
with a study by Garg A, Venkatesh V, singh M et.al, in 2004.
In this study, direct microscopic examination was positive in 
25.8%  samples,  culture  yields  growth  in  15.7%.Both  positivity  was 
reported in 58.4% of the samples.
Although  the  microscopic  examination  is  simple  and  gives 
quicker  results,  culture  remains  the  gold  standard  because  of  its 
specificity for genus and species identification.
In  our  study  nondermatophyte  moulds  were  isolated  in 
majority  (51.8%) followed by yeasts  (26.8%), dermatophytes  (21.4%). 
Until  recently,  yeasts  were  regarded  as  contaminants  but  increasingly 
they are emerging as pathogens.66
The role of aspergillus species as pathogens has been a topic of 
controversy as they are commonly considered as contaminants. However 
various  recent  studies  and case  reports  have  confirmed  its  pathogenic 
role.
Grover reported Aspergillus niger as a causative pathogen of 
onychomycosis67.  Veer  et.al,  also  reported  50%.  Aspergillus  species 
isolated out of total 13.6% NDM fungal isolates64.
Ramani  et.al,  reported  curvalaria  as  causative  pathogen  in 
IJDVL may 2004.
Onychomycosis  is  known  to  be  difficult  to  treat  and  often 
exerts a significant negative impact on the quality of life. The agents most 
commonly used for  treatment  of onychomycosis  are Griseofulvin,  oral 
Fluconazole, Itraconazole, Terbinafine and topical ciclopiroxolamine and 
amorolfine.
The  newer  antifungal  agents  have  better  pharmacokinetic 
profiles such as prompt penetration of the nail and nail bed, persistence in 
the nail for several months even after the discontinuation of therapy and 
fewer adverse reactions.
Baran et.al, studied the efficacy of a combination therapy with 
amorolfine  nail  lacquer  and  oral  terbinafine  in  comparison  to  oral 
terbinafine  alone  for  the  treatment  of  onychomycosis  and  concluded 
combination enhances clinical efficacy and is more cost effective68.
In  our  study  even  though  the  combination  therapy  gave 
mycological  cure rate higher than terbinafine monotherapy it  does not 
have statistically significant difference (p value 0.62) in efficacy than that 
of terbinafine monotherapy which is also cost effective and ensuring that 
the patients are likely to complete the therapy.
CONCLUSION
 Females are more commonly affected than males.
 Common age group is between 31-60 yrs 
 Trauma, Diabetes were found to be the precipitating factor.
 Finger nail involvement is found more than toe nail involvement.
 Distal and lateral subungual onychomycosis is the commonest 
type.
 Nondermatophyte moulds are commonly isolated than 
dermatophytes , yeasts.
 No specific systemic disease  association is  noted in this study.
 Therapeutic trial concludes that terbinafine monotherapy is as good 
as combination therapy.
The  clinicoetiological  correlation  reveals  that  a  single 
pathogen may give rise to various clinical types. The recognition of the 
changing  prevalence  of  etiological  agents  will  aid  in  the  therapeutic 
approach and the potential implementation of the control measures. The 
efficacy, short duration, lesser side effects, cost effectiveness of the drug 
(particularly Terbinafine) gives a positive approach in the treatment of 
onychomycosis.
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SUBRAMANI 47/M Manson 4 Y - - - - - - - 3 TDO - -
KOH +;C- Aspergillus 
niger A + +
ANDAL 60/F House wife 2 Y - - - - - - 2 10 PSO/TDO - -
KOH +;C- Aspergillus 
niger B - -
JESIMA 37/F House wife 6 M - - - - - - 3 5 PSO - KP/I ntertrigo
KOH +;C- Nonalbicans 
candida C + +
SANTHA 42/F House wife 2 M - - - - - - 3 1 DLSO/TDO - - KOH +; C- Neg -
SARASWATHY 60/F House wife 1 Y - + - - - - 4 2 DLSO - - KOH +; C- Rhizopus A + +
SUNDAR 42/M
Manual 
labourer 1 M + - - - + - 3 6 PSO/TDO - TV
KOH +; C- Aspergillus 
niger B - -
RAMZAN 40/F House wife 4 Y - - - - - - 7 5 TDO - -
KOH +; C- Candida 
albicans C + +
DEVADAS 38/M Contractor 4 Y - - - - - - 4 2 TDO - - KOH +; C- Neg -
SANTHABAI 60/F
Water board 
worker 4 Y - - - - - - 7 4 TDO - -
KOH +; C- Nonalbicans 
candida A + +
KABITHA BEGAM 37/F House wife 1 Y + + + - - - - 7 TDO - Vitiligo
KOH +; C- Aspergillus 
niger B - -
PRASITHA 40/F House wife 4 M - - - - - - 10 5 DLSO/TDO - -
KOH +; C- Aspergillus 
niger C + -
CHELLAMMAL 40/F House wife 3 Y - - - - - - 6 2 DLSO/TDO - -
KOH -; C- Aspergillus 
niger -
DHANALAKSHMI 26/F House wife 5 Y - - - - - - 3 2 PSO - - KOH+; C- Curvalaria A - -
GOPI 29/M Teacher 10 Y - - - - - - 1 - DLSO - -
KOH +; C- Aspergillus 
niger B - -
NARESH 15/M Student 1 Y - - - - - - 4 - TDO - -
KOH +; C- 
Syncephalastrum C - -
MEENACHI 28/F House wife 6 M - - - - - - 5 - DLSO - - KOH -; C- Rhizopus -
PARVATHY 60/F House wife 3 Y - + - - - - - 3 TDO - - KOH +; C- Neg -
DHAVAMANI 58/F 
Water board 
worker 6 M - - - - - - 5 10 TDO + -
KOH +; C- Aspergillus 
niger A + +
GANESAN 50/M Barber 6 M - + - - + - 7 - TDO - Hansen`s
KOH +; C- 
Trichophyton rubrum B - -
VELLAAISAMY 65/M Cloth seller 6 M - - - - + + 7 8 TDO - - KOH +; C- Rhizopus C + +
KASTHURI 52/F House wife 6 M - - - + - - - 2 DLSO + Hypothyroidism/Vitiligo
KOH -; C- Aspergillus 
niger -
GANDHIMATHI 57/F House wife 2 M - - - - - - - 2 DLSO + - KOH +; C- Neg -
SRIDHAR 18/M Student 1 Y + - - - - - 1 - DLSO - - KOH +; C- Neg A + +
VALLI 17/F Bottle washer 1 Y - - - - - - - 1 DLSO - -
KOH +; C- Candida 
albicans B + +
VACHALLA 36/F Office staff 2 Y - - - + - - 1 - DLSO + Pitting
KOH +; C- Candida 
albicans C - -
SUNDARI 38/F House wife 4 Y - - - - - 2 2 DLSO - -
KOH -; C- Aspergillus 
niger -
PARIMALA 44/F House wife 3 M - - - - - - 2 - DLSO/TDO - -
KOH -; C- Aspergillus 
niger -
MAHESH 20/F Sweeper 6 M + - - - - + 5 - TDO - - KOH +; C- Curvalaria A + -
VALLIAMMAL 70/F House wife 1 Y + - + - - - - 5 TDO - TV
KOH +; C- Nonalbicans 
Candida B - -
RENUGA 32/F House wife 3 M - - - - - - 5 2 DLSO - -
KOH +; C- Nonalbicans 
candida C + +
PARVATHY 50/F House wife 1 Y - - - - - - 4 2 TDO - Pitting
KOH -; C- Aspergillus 
niger -
MARIMUTHU 32/M Office staff 2 M - - + - - - 7 6 TDO - Perforating folliculitis KOH +; C- Neg -
RAJAN 21/M Postal staff 1 Y - - - - - + 2 - DLSO/TDO - -
KOH +; C- 
Syncephalastrum A - -
SARASWATHY 59/F Juice maker 1 Y - - + - - - 3 2 DLSO - -
KOH +; C- Aspergillus 
niger B - -
KANNAN 54/M Office staff 2 Y - - - - - - 6 4 PSO/TDO - -
KOH +; C- 
Trichophyton rubrum C + +
RAMATHAI 43/F House wife 3 M - - - - - - 4 2 DLSO/TDO - - KOH +; C- Neg -
MAHESHVARI 35/F House wife 8 M - - - - - 3 - TDO - - KOH +; C- Neg -
MALLIGA BEEVI 65/F House wife 3 M - + - - - - - 6 DLSO - -
KOH +; C- 
Trichophyton 
verrucosum A + +
BHAVANI 26/F House wife 2 Y - - - - - - 4 - DLSO - Morphea
KOH +; C- Aspergillus 
niger B + -
LAKSHMI 38/F 
Rice mill 
labourer 4 Y - - - - - - 6 3 DLSO/TDO - -
KOH +; C- 
Trichophyton 
schoenlenii C + +
RAMTHULASI 60/F Farmer 10 Y - - - - - - 3 3 TDO - -
KOH -; C- Aspergillus 
niger -
KALIYAN 45/M Farmer 8 M - - - - - - 2 10 DLSO - Hansen`s KOH +; C- Neg -
LATHA 25/F House wife 1 Y - - - - - - 1 - DLSO - - KOH +; C- Neg -
SRIPAL 59/M Driver 2 M - - - - + + 5 - PSO - Psoriasis
KOH +; C- Aspergillus 
niger A - -
MANIKANDAN 18/M Student 3 Y - - - - - - - 2 DLSO - - KOH +; C- Rhizopus B + +
ANJALIDEVI 52/F House wife 3 M - + + - - - 1 - PSO - -
KOH -; C- 
Trichophyton rubrum C + +
SORNAKILI 60/F House wife 2 M - - + - - - 2 - TDO - - KOH +; C- Neg -
RAJAVALLI 55/F Servant maid 2 M - - - - - - 4 1 TDO - Intertrigo KOH +; C- Neg -
ASAN PATHIMA 3/F - 7 M - - - - - - 2 - TDO - - KOH +; C- Neg -
SHAKILA 21/F House wife 1 Y - - - - - - 10 - DLSO - -
KOH +; C- Nonalbicans 
candida A + -
SUTHAN 22/M Student 2 M - - - - - - 10 - SWO - Pitting
KOH +; C- 
Trichophyton.rubrum B - -
RAVI 32/M Welder 1 Y + - + - + + 2 - DLSO - -
KOH +; C- Candida 
albicans C + -
KALISHA 32/M Chemist 3 M - - - - - - 4 6 DLSO - -
KOH +; C- 
Trichophyton 
mentagrophytes A + +
KALA 55/F Farmer 4 M - + + - - - 2 10 TDO - -
KOH -; C- Aspergillus 
niger -
NAMASIVAYAM 64/M Watchman 5 Y + - - - - - 7 2 DLSO - Filaria
KOH -; C- Aspergillus 
niger -
SUNDARAM 30/M Medical staff 7 M - - - - - - - 1 DLSO - -
KOH +; C- 
Trichophyton 
schoenlenii B + +
RAMBHAI 60/F House wife 4 M - - - - - - 4 1 DLSO + -
KOH +; C- 
Syncephalastrum C + +
PONURANGAM 47/M Farmer 3 Y - - - - + - 8 2 DLSO - -
KOH +; C- 
Aureobasidium 
pullalens A - -
RAMESH 27/M Hotel staff 1 M - - - - + + 3 - DLSO - -
KOH +; C- Candida 
albicans B + +
SAROJA 65/F Servant maid 1 M - - - - - - 1 - PSO - -
KOH +; C- Aspergillus 
niger C + +
NAGARATHINAM 50/F Farmer 1 Y - + + - - - 2 4 TDO - Psoriasis
KOH +; C- Nonalbicans 
candida A + +
GUNASEKARAN 44/M Farmer 2 Y - + - - - - 6 2 TDO - Seizure disorer
KOH +; C- 
Trichophyton 
verrucosum B + +
MURUGAIYA 58/M Merchant 1 Y - - - - - - 5 2 DLSO - - KOH +; C- Neg C + +
ARUMUGAM 67/M Hotel staff 6 M - - - - + - 5 - DLSO + -
KOH +; C- Aspergillus 
niger A - -
GOWTHAMI 55/F House wife 3 M - - - - - - 3 2 DLSO - Vitiligo
KOH -; C- Aspergillus 
niger -
DHARA 41/F House wife 1 M - - - - - - 2 4 DLSO + Keratolysis punctata
KOH -; C- Nonalbicans 
candida -
ALAGESAN 64/M Manson 1 M - - - - - - 5 2 TDO - Psoriasis KOH +; C- Rhizopus B + +
VICKEY 32/M Electrician 5 Y + - - - + - 1 5 DLSO + - KOH +; C- Neg C + +
JASWANTH 31/M Merchant 5 Y - - - - - - 10 - SWO/TDO - Pitting KOH +; C- Rhizopus A - -
ROSI 60/F Office staff 5 M - - - - - - - 2 DLSO - -
KOH +; C- 
Scopulariopsis B - -
SUSIRAJ 42/M Driver 1 Y - - + - - - 2 - DLSO + - KOH +; C- Neg C + +
RAMESH 21/M Office staff 2 M - - - - - - 3 - DLSO + Renal transplanted
KOH +; C- Candida 
albicans A - -
REVATHI 18/M Student 5 Y - - - - - - 3 - TDO - Nevus achromicus
KOH +; C- 
Trichophyton.violaceum B + +
RUKUMANI 35/F House wife 3 M - - - + - - 5 2 DLSO/TDO - -
KOH +; C- 
Syncephalastrum C + +
GLARA 50/F House wife 3 M - - - - - - 1 - PSO - -
KOH +; C- Aspergillus 
niger A + +
RAMANI 49/F House wife 1 Y - - - - - - 2 5 DLSO - -
KOH +; C- 
Aureobasidium 
pullalens B + +
GOPALAKRISHNAN 45/M Welder 2 Y + - + - + + 5 5 DLSO/TDO + -
KOH +; C- Aspergillus 
niger C + +
PRABAKARAN 30/M LIC agent 1 M + - - - - - 1 - DLSO - -
KOH -; C- 
Trichophyton.rubrum A + +
PECHIAMMAL 59/F House wife 2 Y + - - - - - 1 - DLSO - -
KOH +; C- Candida 
albicans B - -
MOHAIDEEN 40/M Electrician 6 M - - - - + + 4 2 PSO/TDO - Onychomadesis KOH +; C- Neg -
RANCHITHKUMAR 30/M Businessman 1 M - - - - - - 2 - DLSO - Renal transplanted KOH +; C- Neg
RAJENDREN 41/M Hotel staff 3 Y - - - - + + 8 - DLSO/TDO - - KOH +; C- Neg C - -
MURALI 17/M Student 1 M - - - - - - 1 - PSO + - KOH +; C- Neg -
ANITHA 29/F House wife 3 Y - - - - - - 2 1 TDO - -
KOH -; C- 
Trichophyton 
mentagrophytes A + +
RAJALAKSHMI 26/F House wife 1 Y - - - - - - 7 3 DLSO + -
KOH +; C- Nonalbicans 
candida B - -
BAMA 20/F House wife 3 M - - - - - - 1 - DLSO - - KOH +; C- Neg -
INDHUMATHI 18/F Student 4 Y + - - + - - 5 - DLSO - - KOH +; C- Neg -
SUMATHI 38/F House wife 2 Wks - + - - - - 5 - TDO + -
KOH +; C- Aspergillus 
niger C - -
PANDURENGAN 54/M Medical staff 6 M - - - - - - 2 - DLSO - - KOH +; C- Neg -
KEY TO MASTER CHART
Sex 
M - Male
F - Female
Duration
Y - Years
M - Months
Wks - Weeks
Past H/o
HT - Hypertension
DM - Diabetes mellitus
Nail
FN - Finger Nail
TN - Toe Nail 
Clinical types
DLSO –Distal and lateral subungual onychomycosis PSO 
 – Proximal subungual onychomycosis
SWO  – Superficial white onychomycosis
TDO   – Total dystrophic onychomycosis
Associated Dermatological Condition
TP - Tines pedis
TM - Tinea manum
TC - Tinea corporis
Other Association
KP - Keratolysis punctata
TV - Tinea versicolar
Lab Diagnosis
KOH - Potassium Hydroxide Examination
C - Culture
Neg - Negative
+ - Positive
- - Negative
PROFORMA
Serial Number
Name Date
Age Address
Sex
Occupation
Complaints:
Duration
Onset
Site
Associated symptoms
Precipitating factor
H/o exposure to STD
Past H/o : HT/DM/Peripheral vascular Disease/ Varicose Veins / 
Immunosuppressive therapy/ Atopic dermatitis.
Family H/o : Other members affected or not.
Personal H/o: Smoking/Alcoholic 
Vegetarian/Mixed diet.
Treatment H/o:  Topical Topical
Allopathic Indigenous 
Systemic    Systemic
General Examination:
Anaemia / Pedal edema / Jaundice / Clubbing/Cyanosis /
Generalized lymphadenopathy
CVS PR
RS BP
Abdomen
CNS
Musculoskeletal System
Nail:
Toe nail / Finger nail
Number of nails
          affected :
Site of origin :
Discolouration : Yellow / Brown / Black
Thickening / Ridging
Subungal hyperkeratosis
Onycholysis
Dystrophy
Paronychia
Types : DLSO / PSO / SWO / TDO /
T.manum / T.pedis
Hair :
Mucosa :
Skin :
Others :
LAB INVESTIGATION
Blood
Hb% SGOT
TC SGPT
DC SAP
ESR STP
Platelet Count STB
B.Sugar KOH Mount
B.Urea Culture
S.Creatine Biopsy
Urine
Albumin
Sugar
Deposits
RX GIVEN
Topical Systemic
Response to therapy
Follow up
Remarks
